Segment, Geographic and Other Revenue Information (Tables)

9 Months Ended

Sep. 27, 2020

Reconciliation of Revenue from Segments to Consolidated


The following summarizes selected income statement information by reportable segment:
	Three Months Ended
	Revenues				Earnings(a)
(MILLIONS OF DOLLARS)	September 27, 2020		September 29, 2019		September 27, 2020		September 29, 2019
Reportable Segments:
Biopharma	$	10,215	$	9,952	$	6,807	$	6,506
Upjohn	1,916		2,351		1,009		1,384
Total reportable segments	12,131		12,303		7,816		7,890
Other business activities	—		377		(1,939)		(1,469)
Reconciling Items:
Corporate and other unallocated	—		—		(1,192)		(1,439)
Purchase accounting adjustments	—		—		(823)		(1,141)
Acquisition-related costs	—		—		(11)		(300)
Certain significant items(b)	—		—		(1,675)		7,187
	$	12,131	$	12,680	$	2,176	$	10,727

	Nine Months Ended
	Revenues				Earnings(a)
(MILLIONS OF DOLLARS)	September 27, 2020		September 29, 2019		September 27, 2020		September 29, 2019
Reportable Segments:
Biopharma	$	30,017	$	28,429	$	20,186	$	18,461
Upjohn	5,944		8,535		3,367		5,635
Total reportable segments	35,961		36,964		23,554		24,096
Other business activities	—		2,098		(4,958)		(3,776)
Reconciling Items:
Corporate and other unallocated	—		—		(3,437)		(4,116)
Purchase accounting adjustments	—		—		(2,545)		(3,357)
Acquisition-related costs	—		—		(46)		(152)
Certain significant items(b)	—		—		(2,554)		6,495
	$	35,961	$	39,062	$	10,014	$	19,190

(a)Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income of $44 million in the third quarter of 2020 and $43 million in the third quarter of 2019, and $196 million in the first nine months of 2020 and $184 million in the first nine months of 2019 from our investment in ViiV. See Note 4.

(b)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. In the third quarter and first nine months of 2020, includes, among other items, intangible asset impairment charges of $900 million, recorded in Other (income)/deductions—net, related to IPR&D assets acquired in connection with our Array acquisition. In the third quarter and first nine months of 2019, includes, among other items, a pre-tax gain of $8.1 billion recorded in (Gain) on completion of Consumer Healthcare JV transaction associated with the completion of the GSK Consumer Healthcare joint venture transaction (See Note 2). Certain significant items are discussed further in Note 3 and Note 4.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated


The following summarizes selected income statement information by reportable segment:
	Three Months Ended
	Revenues				Earnings(a)
(MILLIONS OF DOLLARS)	September 27, 2020		September 29, 2019		September 27, 2020		September 29, 2019
Reportable Segments:
Biopharma	$	10,215	$	9,952	$	6,807	$	6,506
Upjohn	1,916		2,351		1,009		1,384
Total reportable segments	12,131		12,303		7,816		7,890
Other business activities	—		377		(1,939)		(1,469)
Reconciling Items:
Corporate and other unallocated	—		—		(1,192)		(1,439)
Purchase accounting adjustments	—		—		(823)		(1,141)
Acquisition-related costs	—		—		(11)		(300)
Certain significant items(b)	—		—		(1,675)		7,187
	$	12,131	$	12,680	$	2,176	$	10,727

	Nine Months Ended
	Revenues				Earnings(a)
(MILLIONS OF DOLLARS)	September 27, 2020		September 29, 2019		September 27, 2020		September 29, 2019
Reportable Segments:
Biopharma	$	30,017	$	28,429	$	20,186	$	18,461
Upjohn	5,944		8,535		3,367		5,635
Total reportable segments	35,961		36,964		23,554		24,096
Other business activities	—		2,098		(4,958)		(3,776)
Reconciling Items:
Corporate and other unallocated	—		—		(3,437)		(4,116)
Purchase accounting adjustments	—		—		(2,545)		(3,357)
Acquisition-related costs	—		—		(46)		(152)
Certain significant items(b)	—		—		(2,554)		6,495
	$	35,961	$	39,062	$	10,014	$	19,190

Schedule of Revenues by Geographic Region


The following summarizes revenues by geographic area:
	Three Months Ended					Nine Months Ended
(MILLIONS OF DOLLARS)	September 27, 2020		September 29, 2019		% Change	September 27, 2020		September 29, 2019		% Change
United States	$	5,716	$	5,850	(2)	$	16,770	$	18,360	(9)
Developed Europe(a)	2,087		2,135		(2)	6,095		6,450		(5)
Developed Rest of World	1,634		1,585		3	4,642		4,758		(2)
Emerging Markets	2,694		3,110		(13)	8,453		9,493		(11)
Revenues	$	12,131	$	12,680	(4)	$	35,961	$	39,062	(8)

(a)Revenues denominated in euros were $1.7 billion in the third quarter of 2020 and $1.7 billion in the third quarter of 2019, and were $4.9 billion in the first nine months of 2020 and $5.2 billion in the first nine months of 2019.

Schedule of Significant Product Revenues

The following provides detailed revenue information for several of our major products:


(MILLIONS OF DOLLARS)		Three Months Ended				Nine Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	Sept. 27, 2020		Sept. 29, 2019		Sept. 27, 2020		Sept. 29, 2019
TOTAL REVENUES		$	12,131	$	12,680	$	35,961	$	39,062
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)		$	10,215	$	9,952	$	30,017	$	28,429
Internal Medicine(a)		$	2,085	$	2,128	$	6,695	$	6,508
Eliquis alliance revenues and direct sales	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	1,114		1,025		3,686		3,121
Chantix/Champix	An aid to smoking cessation treatment in adults 18 years of age or older	223		276		728		825
Premarin family	Symptoms of menopause	168		182		471		542
BMP2	Development of bone and cartilage	70		66		197		212
Toviaz	Overactive bladder	59		61		183		186
All other Internal Medicine	Various	451		517		1,429		1,621
Oncology		$	2,761	$	2,350	$	7,843	$	6,547
Ibrance	Metastatic breast cancer	1,357		1,283		3,955		3,677
Xtandi alliance revenues	mCRPC, nmCRPC, mCSPC	266		225		741		594
Sutent	Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor	202		224		616		704
Inlyta	Advanced RCC	195		139		559		316
Xalkori	ALK-positive and ROS1-positive advanced NSCLC	122		130		409		385
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	111		90		324		267
Retacrit(b)	Anemia	102		64		278		147
Lorbrena	ALK-positive metastatic NSCLC	55		32		142		77
Braftovi	In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant metastatic colorectal cancer after prior therapy	42		18		116		18
Mektovi	In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation	34		19		103		19


(MILLIONS OF DOLLARS)		Three Months Ended				Nine Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	Sept. 27, 2020		Sept. 29, 2019		Sept. 27, 2020		Sept. 29, 2019
Ruxience(b)	Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis	59		—		78		—
All other Oncology	Various	217		125		522		342
Hospital(a), (c)		$	1,728	$	1,840	$	5,535	$	5,505
Sulperazon	Bacterial infections	143		163		432		505
Medrol	Anti-inflammatory glucocorticoid	87		109		295		348
Zithromax	Bacterial infections	25		77		218		254
Precedex	Sedation agent in surgery or intensive care	55		36		211		116
Vfend	Fungal infections	52		87		201		265
Panzyga	Primary humoral immunodeficiency	62		46		199		107
Fragmin	Treatment/prevention of venous thromboembolism	60		62		178		185
Zyvox	Bacterial infections	51		61		176		195
Pfizer CentreOne(d)	Various	242		176		618		556
All other Anti-infectives	Various	384		434		1,195		1,260
All other Hospital(c)	Various	568		589		1,813		1,713
Vaccines		$	1,717	$	1,808	$	4,574	$	4,795
Prevnar 13/Prevenar 13	Pneumococcal disease	1,534		1,603		4,100		4,268
Nimenrix	Meningococcal disease	50		52		180		159
FSME/IMMUN-TicoVac	Tick-borne encephalitis disease	77		64		170		197
All other Vaccines	Various	56		89		124		171
Inflammation & Immunology (I&I)		$	1,173	$	1,226	$	3,299	$	3,482
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis	654		599		1,741		1,634
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	321		415		1,005		1,285
Inflectra/Remsima(b)	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	162		155		471		446
All other I&I	Various	35		58		83		116
Rare Disease		$	752	$	601	$	2,071	$	1,592
Vyndaqel/Vyndamax	ATTR-cardiomyopathy and polyneuropathy	351		156		859		259
BeneFIX	Hemophilia B	107		125		337		372
Genotropin	Replacement of human growth hormone	107		124		316		357
Refacto AF/Xyntha	Hemophilia A	92		104		272		319
Somavert	Acromegaly	67		64		198		192
All other Rare Disease	Various	27		28		89		94
UPJOHN(a)		$	1,916	$	2,351	$	5,944	$	8,535
Lipitor	Reduction of LDL cholesterol	356		476		1,191		1,506
Lyrica	Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury	352		527		1,058		2,888
Norvasc	Hypertension	183		219		601		735
Celebrex	Arthritis pain and inflammation, acute pain	133		179		428		526
Viagra	Erectile dysfunction	121		120		342		379
Effexor	Depression and certain anxiety disorders	80		80		242		242
Zoloft	Depression and certain anxiety disorders	76		74		233		217
EpiPen(a)	Epinephrine injection used in treatment of life-threatening allergic reactions	58		74		194		197
Xalatan/Xalacom	Glaucoma and ocular hypertension	62		68		188		201
Xanax	Anxiety disorders	55		50		149		147
All other Upjohn	Various	442		485		1,317		1,496
CONSUMER HEALTHCARE BUSINESS(e)		$	—	$	377	$	—	$	2,098
Total Alliance revenues		$	1,250	$	1,141	$	4,036	$	3,418
Total Biosimilars(b)		$	424	$	236	$	1,001	$	632
Total Sterile Injectable Pharmaceuticals(f)		$	1,195	$	1,248	$	3,839	$	3,703

(a)Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues

associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.

(b)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit and Ruxience.

(c)Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.

(d)Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.

(e)On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. See Note 2B.

(f)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.